Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) EPS (Weighted Average and Diluted) (2016 - 2024)

Crescent Biopharma (CBIO) has disclosed EPS (Weighted Average and Diluted) for 9 consecutive years, with -$0.16 as the latest value for Q3 2024.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 14.29% to -$0.16 in Q3 2024 year-over-year; TTM through Sep 2024 was -$0.62, a 1.59% increase, with the full-year FY2024 number at -$0.59, down 1.72% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.16 for Q3 2024 at Crescent Biopharma, up from -$0.28 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.04 in Q1 2024 to a low of -$0.34 in Q4 2020.
  • A 5-year average of -$0.22 and a median of -$0.22 in 2022 define the central range for EPS (Weighted Average and Diluted).
  • Biggest YoY gain for EPS (Weighted Average and Diluted) was 76.47% in 2024; the steepest drop was 115.38% in 2024.
  • Crescent Biopharma's EPS (Weighted Average and Diluted) stood at -$0.34 in 2020, then rose by 3.05% to -$0.33 in 2021, then soared by 42.42% to -$0.19 in 2022, then rose by 26.32% to -$0.14 in 2023, then dropped by 14.29% to -$0.16 in 2024.
  • Per Business Quant, the three most recent readings for CBIO's EPS (Weighted Average and Diluted) are -$0.16 (Q3 2024), -$0.28 (Q2 2024), and -$0.04 (Q1 2024).